E2007

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Parkinson's Disease

Conditions

Parkinson's Disease

Trial Timeline

Feb 1, 2006 → Aug 1, 2007

NCT ID

NCT00286897

About E2007

E2007 is a phase 3 stage product being developed by Eisai for Parkinson's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00286897. Target conditions include Parkinson's Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03201900	Phase 3	Completed	Jun 28, 2017	Jul 27, 2020	Partial Onset Seizures
NCT02116907	Phase 1	Completed	May 1, 2014	Sep 1, 2014	Healthy Subjects
NCT00849212	Phase 2	Completed	Apr 1, 2009	Nov 1, 2009	Refractory Partial Seizures
NCT00592904	Phase 2/3	Completed	Jan 1, 2008	Jul 1, 2011	Neuralgia
NCT00451633	Phase 2	Withdrawn	Mar 1, 2007	—	Parkinson's Disease
NCT00427011	Phase 2	Terminated	Feb 1, 2007	Apr 1, 2008	Parkinson's Disease
NCT00360412	Phase 3	Terminated	Oct 1, 2006	Apr 1, 2008	Parkinson's Disease
NCT00286897	Phase 3	Completed	Feb 1, 2006	Aug 1, 2007	Parkinson's Disease
NCT00165789	Phase 2	Completed	Sep 1, 2005	Sep 1, 2006	Parkinson's Disease
NCT00154063	Phase 2	Completed	Jan 1, 2005	Jun 1, 2006	Migraine Prophylaxis

Competing Products

20 competing products in Parkinson's Disease

See all competitors

Product	Company	Stage	Hype Score
UB-312 + Placebo	Vaxxinity	Phase 1	25
NAV5001 + DaTscan	Navidea Biopharmaceuticals	Phase 3	69
piclozotan + 0.9% sodium chloride (normal saline)	Daiichi Sankyo	Phase 2	52
E2007	Eisai	Phase 3	77
ARICEPT	Eisai	Phase 3	77
Perampanel	Eisai	Phase 3	77
GPI 1485	Eisai	Phase 2	52
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo	Eisai	Phase 3	77
perampanel + placebo	Eisai	Phase 2	52
Lemborexant + placebo	Eisai	Approved	85
Placebo + E2007 + E2007	Eisai	Phase 3	77
E2007 + E2007 + E2007	Eisai	Phase 2	52
E2007	Eisai	Phase 2	52
E2007	Eisai	Phase 2	52
E2007	Eisai	Phase 2	52
2 mg perampanel + 4 mg perampanel + placebo comparator	Eisai	Phase 3	77
Istradefylline (KW-6002)	Kyowa Kirin	Phase 2	52
Istradefylline 20 mg or 40 mg	Kyowa Kirin	Phase 3	77
Istradefylline (KW-6002)	Kyowa Kirin	Phase 3	77
Perampanel	Eisai	Phase 2	52

Other Products from Eisai

MecobalaminApproved

MonteplaseApproved

E2020 + PlaceboApproved

Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved

DonepezilApproved